<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39337964</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>HLA-C Peptide Repertoires as Predictors of Clinical Response during Early SARS-CoV-2 Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1181</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life14091181</ELocationID><Abstract><AbstractText>The human leukocyte antigen (HLA) system plays a pivotal role in the immune response to viral infections, mediating the presentation of viral peptides to T cells and influencing both the strength and specificity of the host immune response. Variations in HLA genotypes across individuals lead to differences in susceptibility to viral infection and severity of illness. This study uses observations from the early phase of the COVID-19 pandemic to explore how specific HLA class I molecules affect clinical responses to SARS-CoV-2 infection. By analyzing paired high-resolution HLA types and viral genomic sequences from 60 patients, we assess the relationship between predicted HLA class I peptide binding repertoires and infection severity as measured by the sequential organ failure assessment score. This approach leverages functional convergence across HLA-C alleles to identify relationships that may otherwise be inaccessible due to allelic diversity and limitations in sample size. Surprisingly, our findings show that severely symptomatic infection in this cohort is associated with disproportionately abundant binding of SARS-CoV-2 structural and non-structural protein epitopes by patient HLA-C molecules. In addition, the extent of overlap between a given patient's predicted HLA-C and HLA-A peptide binding repertoires correlates with worse prognoses in this cohort. The findings highlight immunologic mechanisms linking HLA-C molecules with the human response to viral pathogens that warrant further investigation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olp</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-3821-435X</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Michigan, 2800 Plymouth Rd Building 35, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laufer</LastName><ForeName>Vincent A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Michigan, 2800 Plymouth Rd Building 35, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valesano</LastName><ForeName>Andrew L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Michigan, 2800 Plymouth Rd Building 35, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Michigan, 2800 Plymouth Rd Building 35, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodside</LastName><ForeName>Kenneth J</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0002-7495-3758</Identifier><AffiliationInfo><Affiliation>Sharing Hope of South Carolina, Charleston, SC 29414, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gift of Life Michigan, Ann Arbor, MI 48108, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academia Invisus LLC, Ann Arbor, MI 48107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yee</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauring</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0003-2906-8335</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine and Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cusick</LastName><ForeName>Matthew F</ForeName><Initials>MF</Initials><Identifier Source="ORCID">0000-0002-0383-9747</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of Michigan, 2800 Plymouth Rd Building 35, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antigenicity</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">computational biology</Keyword></KeywordList><CoiStatement>Kenneth J Woodside is the owner of Academia Invisus LLC. Other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337964</ArticleId><ArticleId IdType="pmc">PMC11433606</ArticleId><ArticleId IdType="doi">10.3390/life14091181</ArticleId><ArticleId IdType="pii">life14091181</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Epidemiology Working Group for NCIP Epidemic Response. Chinese Center for Disease Control and Prevention The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145–151.</Citation><ArticleIdList><ArticleId IdType="pubmed">32064853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Wang Y., Chen Y., Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J. Med. Virol. 2020;92:568–576. doi: 10.1002/jmv.25748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25748</ArticleId><ArticleId IdType="pmc">PMC7228347</ArticleId><ArticleId IdType="pubmed">32134116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z., Peng F., Xu B., Zhao J., Liu H., Peng J., Li Q., Jiang C., Zhou Y., Liu S., et al. Risk factors of critical &amp; mortal COVID-19 cases: A systematic literature review and meta-analysis. J. Infect. 2020;81:e16–e25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177098</ArticleId><ArticleId IdType="pubmed">32335169</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulder P.J.R., Walker B.D. HIV and HLA class I: An evolving relationship. Immunity. 2012;37:426–440. doi: 10.1016/j.immuni.2012.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.09.005</ArticleId><ArticleId IdType="pmc">PMC3966573</ArticleId><ArticleId IdType="pubmed">22999948</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrington M., Nelson G.W., Martin M.P., Kissner T., Vlahov D., Goedert J.J., Kaslow R., Buchbinder S., Hoots K., O’Brien S.J. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999;283:1748–1752. doi: 10.1126/science.283.5408.1748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.283.5408.1748</ArticleId><ArticleId IdType="pubmed">10073943</ArticleId></ArticleIdList></Reference><Reference><Citation>Diouf K., Sarr A.D., Eisen G., Popper S., Mboup S., Kanki P. Associations between MHC class I and susceptibility to HIV-2 disease progression. J. Hum. Virol. 2002;5:1–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12352262</ArticleId></ArticleIdList></Reference><Reference><Citation>International HIV Controllers Study. Pereyra F., Jia X., McLaren P.J., Telenti A., de Bakker P.I.W., Walker B.D., Ripke S., Brumme C.J., Pulit S.L., et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330:1551–1557. doi: 10.1126/science.1195271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1195271</ArticleId><ArticleId IdType="pmc">PMC3235490</ArticleId><ArticleId IdType="pubmed">21051598</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zou Z.Q., Wang K. Clinical relevance of HLA gene variants in HBV infection. J. Immunol. Res. 2016;2016:9069375. doi: 10.1155/2016/9069375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/9069375</ArticleId><ArticleId IdType="pmc">PMC4875979</ArticleId><ArticleId IdType="pubmed">27243039</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo P., Gonçalves G., Latini F., Ferreira O., Porto L.C., Barreto J.A., Girao M.J.C., Diaz R.S. KIR and a specific HLA-C gene are associated with susceptibility and resistance to hepatitis B virus infection in a Brazilian population. Cell. Mol. Immunol. 2014;11:609–612. doi: 10.1038/cmi.2014.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2014.29</ArticleId><ArticleId IdType="pmc">PMC4220832</ArticleId><ArticleId IdType="pubmed">24842861</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes-Cano M.A., Caro-Oleas J.L., Romero-Gómez M., Diago M., Andrade R., Carmona I., Aguilar Reina J., Núñez-Roldán A., González-Escribano M.F. HLA-C and KIR genes in hepatitis C virus infection. Hum. Immunol. 2005;66:1106–1109. doi: 10.1016/j.humimm.2006.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2006.02.001</ArticleId><ArticleId IdType="pubmed">16571411</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S.K., Han J.Y., Pyo C.W., Yang J.M., Jang J.W., Kim C.W., Chang U.I., Bae S.H., Choi J.Y., Chung K.W., et al. Association between human leukocytes antigen alleles and chronic hepatitis C virus infection in the Korean population. Liver Int. 2005;25:1122–1127. doi: 10.1111/j.1478-3231.2005.01105.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2005.01105.x</ArticleId><ArticleId IdType="pubmed">16343061</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivić I., Bradarić N., Puizina-Ivić N., Ledina D., Luksić B., Martinić R. Hla-Cw7 allele as predictor of favorable therapeutic response to interferon-alpha in patients with chronic hepatitis C. Croat. Med. J. 2007;48:807–813. doi: 10.3325/cmj.2007.6.807.</Citation><ArticleIdList><ArticleId IdType="doi">10.3325/cmj.2007.6.807</ArticleId><ArticleId IdType="pmc">PMC2213809</ArticleId><ArticleId IdType="pubmed">18074415</ArticleId></ArticleIdList></Reference><Reference><Citation>Frleta D., Yu C.I., Klechevsky E., Flamar A.L., Zurawski G., Banchereau J., Palucka A.K. Influenza virus and poly(I:C) inhibit MHC class I-restricted presentation of cell-associated antigens derived from infected dead cells captured by human dendritic cells. J. Immunol. 2009;182:2766–2776. doi: 10.4049/jimmunol.0801720.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0801720</ArticleId><ArticleId IdType="pmc">PMC2665125</ArticleId><ArticleId IdType="pubmed">19234171</ArticleId></ArticleIdList></Reference><Reference><Citation>Boon A.C.M., de Mutsert G., Graus Y.M.F., Fouchier R.A.M., Sintnicolaas K., Osterhaus A.D.M.E., Rimmelzwaan G.F. Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J. Virol. 2002;76:2567–2572. doi: 10.1128/jvi.76.5.2567-2572.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.76.5.2567-2572.2002</ArticleId><ArticleId IdType="pmc">PMC153818</ArticleId><ArticleId IdType="pubmed">11836437</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta M., Dutta P., Medhi S., Borkakoty B., Biswas D. Polymorphism of HLA class I and class II alleles in influenza A(H1N1)pdm09 virus infected population of Assam, Northeast India. J. Med. Virol. 2018;90:854–860. doi: 10.1002/jmv.25018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25018</ArticleId><ArticleId IdType="pubmed">29315655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M., Tseng H.K., Trejaut J.A., Lee H.L., Loo J.H., Chu C.C., Chen P.J., Su Y.W., Lim K.H., Tsai Z.U., et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med. Genet. 2003;4:9. doi: 10.1186/1471-2350-4-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2350-4-9</ArticleId><ArticleId IdType="pmc">PMC212558</ArticleId><ArticleId IdType="pubmed">12969506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Mazas A. HLA studies in the context of coronavirus outbreaks. Swiss Med. Wkly. 2020;150:w20248. doi: 10.4414/smw.2020.20248.</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2020.20248</ArticleId><ArticleId IdType="pubmed">32297958</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceraolo C., Giorgi F.M. Genomic variance of the 2019-nCoV coronavirus. J. Med. Virol. 2020;92:522–528. doi: 10.1002/jmv.25700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25700</ArticleId><ArticleId IdType="pmc">PMC7166773</ArticleId><ArticleId IdType="pubmed">32027036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30251-8</ArticleId><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner J., Suwalski P., Holtgrewe M., Rakitko A., Thibeault C., Müller M., Patriki D., Quedenau C., Krüger U., Ilinsky V., et al. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021;40:101099. doi: 10.1016/j.eclinm.2021.101099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101099</ArticleId><ArticleId IdType="pmc">PMC8410317</ArticleId><ArticleId IdType="pubmed">34490415</ArticleId></ArticleIdList></Reference><Reference><Citation>Khor S.S., Omae Y., Nishida N., Sugiyama M., Kinoshita N., Suzuki T., Suzuki M., Suzuki S., Izumi S., Hojo M., et al. HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, age and sex are associated with severity of Japanese COVID-19 with respiratory failure. Front. Immunol. 2021;12:658570. doi: 10.3389/fimmu.2021.658570.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.658570</ArticleId><ArticleId IdType="pmc">PMC8100314</ArticleId><ArticleId IdType="pubmed">33968060</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzurez A., Naka I., Miki S., Nakayama-Hosoya K., Isshiki M., Watanabe Y., Nakamura-Hoshi M., Seki S., Matsumura T., Takano T., et al. Association of HLA-DRB1*09:01 with severe COVID-19. HLA. 2021;98:37–42. doi: 10.1111/tan.14256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.14256</ArticleId><ArticleId IdType="pmc">PMC8251239</ArticleId><ArticleId IdType="pubmed">33734601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Huang S., Gao R., Zhou Y., Lai C., Li Z., Xian W., Qian X., Li Z., Huang Y., et al. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov. 2020;6:83. doi: 10.1038/s41421-020-00231-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-00231-4</ArticleId><ArticleId IdType="pmc">PMC7653987</ArticleId><ArticleId IdType="pubmed">33298875</ArticleId></ArticleIdList></Reference><Reference><Citation>Langton D.J., Bourke S.C., Lie B.A., Reiff G., Natu S., Darlay R., Burn J., Echevarria C. The influence of HLA genotype on the severity of COVID-19 infection. HLA. 2021;98:14–22. doi: 10.1111/tan.14284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.14284</ArticleId><ArticleId IdType="pmc">PMC8251294</ArticleId><ArticleId IdType="pubmed">33896121</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi S., Ghasemi-Basir H.R., Majzoobi M.M., Rasouli-Saravani A., Hajilooi M., Solgi G. HLA-DRB1*04 may predict the severity of disease in a group of Iranian COVID-19 patients. Hum. Immunol. 2021;82:719–725. doi: 10.1016/j.humimm.2021.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2021.07.004</ArticleId><ArticleId IdType="pmc">PMC8275473</ArticleId><ArticleId IdType="pubmed">34294460</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigón L., Galán M., Torres M., Martín-Galiano A.J., Rodríguez-Mora S., Mateos E., Corona M., Malo R., Navarro C., Murciano-Antón M.A., et al. Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort. PLoS ONE. 2022;17:e0272867. doi: 10.1371/journal.pone.0272867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0272867</ArticleId><ArticleId IdType="pmc">PMC9374209</ArticleId><ArticleId IdType="pubmed">35960731</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto D.G., Murdolo L.D., Chatzileontiadou D.S.M., Sabatino J.J., Jr., Yusufali T., Peyser N.D., Butcher X., Kizer K., Guthrie K., Murray V.W., et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature. 2023;620:128–136. doi: 10.1038/s41586-023-06331-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06331-x</ArticleId><ArticleId IdType="pmc">PMC10396966</ArticleId><ArticleId IdType="pubmed">37468623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolday D., Fung C.Y.J., Morgan G., Casalino S., Frangione E., Taher J., Lerner-Ellis J.P. HLA variation and SARS-CoV-2 specific antibody response. Viruses. 2023;15:906. doi: 10.3390/v15040906.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040906</ArticleId><ArticleId IdType="pmc">PMC10143129</ArticleId><ArticleId IdType="pubmed">37112884</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanevich O.V., Alekseeva E.I., Sergeeva M., Fadeev A.V., Komissarova K.S., Ivanova A.A., Simakova T.S., Vasilyev K.A., Shurygina A.P., Stukova M.A., et al. SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19. Nat. Commun. 2023;14:149. doi: 10.1038/s41467-022-34033-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34033-x</ArticleId><ArticleId IdType="pmc">PMC9831376</ArticleId><ArticleId IdType="pubmed">36627290</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava A., Hollenbach J.A. The immunogenetics of COVID-19. Immunogenetics. 2023;75:309–320. doi: 10.1007/s00251-022-01284-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-022-01284-3</ArticleId><ArticleId IdType="pmc">PMC9762652</ArticleId><ArticleId IdType="pubmed">36534127</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoseinnezhad T., Soltani N., Ziarati S., Behboudi E., Mousavi M.J. The role of HLA genetic variants in COVID-19 susceptibility, severity, and mortality: A global review. J. Clin. Lab. Anal. 2024;38:e25005. doi: 10.1002/jcla.25005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.25005</ArticleId><ArticleId IdType="pmc">PMC10829690</ArticleId><ArticleId IdType="pubmed">38251811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S.F., Quadeer A.A., McKay M.R. Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12:254. doi: 10.3390/v12030254.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12030254</ArticleId><ArticleId IdType="pmc">PMC7150947</ArticleId><ArticleId IdType="pubmed">32106567</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.H., Koohy H. In silico identification of vaccine targets for 2019-nCoV. F1000Research. 2020;9:145. doi: 10.12688/f1000research.22507.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.22507.2</ArticleId><ArticleId IdType="pmc">PMC7111504</ArticleId><ArticleId IdType="pubmed">32269766</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen A., David J.K., Maden S.K., Wood M.A., Weeder B.R., Nellore A., Thompson R.F. Human leukocyte antigen susceptibility map for severe acute respiratory syndrome Coronavirus 2. J. Virol. 2020;94:10–1128. doi: 10.1128/JVI.00510-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00510-20</ArticleId><ArticleId IdType="pmc">PMC7307149</ArticleId><ArticleId IdType="pubmed">32303592</ArticleId></ArticleIdList></Reference><Reference><Citation>Enayatkhani M., Hasaniazad M., Faezi S., Gouklani H., Davoodian P., Ahmadi N., Einakian M.A., Karmostaji A., Ahmadi K. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: An in silico study. J. Biomol. Struct. Dyn. 2021;39:2857–2872. doi: 10.1080/07391102.2020.1756411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1756411</ArticleId><ArticleId IdType="pmc">PMC7196925</ArticleId><ArticleId IdType="pubmed">32295479</ArticleId></ArticleIdList></Reference><Reference><Citation>Charonis S.A., James L.M., Georgopoulos A.P. SARS-CoV-2 in silico binding affinity to human leukocyte antigen (HLA) Class II molecules predicts vaccine effectiveness across variants of concern (VOC) Sci. Rep. 2022;12:8074. doi: 10.1038/s41598-022-11956-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-11956-5</ArticleId><ArticleId IdType="pmc">PMC9109665</ArticleId><ArticleId IdType="pubmed">35577837</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynisson B., Alvarez B., Paul S., Peters B., Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48:W449–W454. doi: 10.1093/nar/gkaa379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa379</ArticleId><ArticleId IdType="pmc">PMC7319546</ArticleId><ArticleId IdType="pubmed">32406916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti A.P., Kula T., Wang Y., Nguyen D.M.V., Weinheimer A., Dunlap G.S., Xu Q., Nabilsi N., Perullo C.R., Cristofaro A.W., et al. Unbiased screens show CD8+ T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2 that largely reside outside the spike protein. Immunity. 2020;53:1095–1107.e3. doi: 10.1016/j.immuni.2020.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.10.006</ArticleId><ArticleId IdType="pmc">PMC7574860</ArticleId><ArticleId IdType="pubmed">33128877</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini S.K., Hersby D.S., Tamhane T., Povlsen H.R., Amaya Hernandez S.P., Nielsen M., Gang A.O., Hadrup S.R. SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients. Sci. Immunol. 2021;6:eabf7550. doi: 10.1126/sciimmunol.abf7550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf7550</ArticleId><ArticleId IdType="pmc">PMC8139428</ArticleId><ArticleId IdType="pubmed">33853928</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulien I., Kemming J., Oberhardt V., Wild K., Seidel L.M., Killmer S., Sagar. Daul F., Salvat Lago M., Decker A., et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. Nat. Med. 2021;27:78–85. doi: 10.1038/s41591-020-01143-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01143-2</ArticleId><ArticleId IdType="pubmed">33184509</ArticleId></ArticleIdList></Reference><Reference><Citation>Nersisyan S., Zhiyanov A., Shkurnikov M., Tonevitsky A. T-CoV: A comprehensive portal of HLA-peptide interactions affected by SARS-CoV-2 mutations. Nucleic Acids Res. 2022;50:D883–D887. doi: 10.1093/nar/gkab701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab701</ArticleId><ArticleId IdType="pmc">PMC8385993</ArticleId><ArticleId IdType="pubmed">34396391</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonça A., Bruining H., Reinhart C.K., Suter P.M., Thijs L.G. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–710. doi: 10.1007/BF01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare S., Gurry C., Freitas L., Schultz M.B., Bach G., Diallo A., Akite N., Ho J., Lee R.T., Yeo W., et al. GISAID’s role in pandemic response. China CDC Wkly. 2021;3:1049–1051. doi: 10.46234/ccdcw2021.255.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2021.255</ArticleId><ArticleId IdType="pmc">PMC8668406</ArticleId><ArticleId IdType="pubmed">34934514</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson J., Barker D.J., Georgiou X., Cooper M.A., Flicek P., Marsh S.G.E. IPD-IMGT/HLA database. Nucleic Acids Res. 2020;48:D948–D955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145640</ArticleId><ArticleId IdType="pubmed">31667505</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirdita M., Schütze K., Moriwaki Y., Heo L., Ovchinnikov S., Steinegger M. ColabFold: Making protein folding accessible to all. Nat. Methods. 2022;19:679–682. doi: 10.1038/s41592-022-01488-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-022-01488-1</ArticleId><ArticleId IdType="pmc">PMC9184281</ArticleId><ArticleId IdType="pubmed">35637307</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J., Evans R., Pritzel A., Green T., Figurnov M., Ronneberger O., Tunyasuvunakool K., Bates R., Žídek A., Potapenko A., et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi: 10.1038/s41586-021-03819-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Bürkner P.C. Advanced Bayesian Multilevel Modeling with the R Package brms. R J. 2018;10:395–411. doi: 10.32614/RJ-2018-017.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/RJ-2018-017</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter B., Gelman A., Hoffman M.D., Lee D., Goodrich B., Betancourt M., Brubaker M., Guo J., Li P., Riddell A. Stan: A Probabilistic Programming Language. J. Stat. Softw. 2017;76:1–32. doi: 10.18637/jss.v076.i01.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v076.i01</ArticleId><ArticleId IdType="pmc">PMC9788645</ArticleId><ArticleId IdType="pubmed">36568334</ArticleId></ArticleIdList></Reference><Reference><Citation>Belsley D.A., Kuh E., Welsch R.E. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. John Wiley &amp; Sons; New York, NY, USA: 1980.</Citation></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T cell responses to SARS-CoV-2 Coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501.e15. doi: 10.1016/j.cell.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W., Rostron T., Supasa P., Liu C., et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 2020;21:1336–1345. doi: 10.1038/s41590-020-0782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0782-6</ArticleId><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen M., Harndahl M., Stryhn A., Boucherma R., Nielsen L.L., Lemonnier F.A., Nielsen M., Buus S. Uncovering the peptide-binding specificities of HLA-C: A general strategy to determine the specificity of any MHC class I molecule. J. Immunol. 2014;193:4790–4802. doi: 10.4049/jimmunol.1401689.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1401689</ArticleId><ArticleId IdType="pmc">PMC4226424</ArticleId><ArticleId IdType="pubmed">25311805</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkizova S., Klaeger S., Le P.M., Li L.W., Oliveira G., Keshishian H., Hartigan C.R., Zhang W., Braun D.A., Ligon K.L., et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 2020;38:199–209. doi: 10.1038/s41587-019-0322-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0322-9</ArticleId><ArticleId IdType="pmc">PMC7008090</ArticleId><ArticleId IdType="pubmed">31844290</ArticleId></ArticleIdList></Reference><Reference><Citation>Neisig A., Melief C.J., Neefjes J. Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. J. Immunol. 1998;160:171–179. doi: 10.4049/jimmunol.160.1.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.160.1.171</ArticleId><ArticleId IdType="pubmed">9551969</ArticleId></ArticleIdList></Reference><Reference><Citation>Apps R., Qi Y., Carlson J.M., Chen H., Gao X., Thomas R., Yuki Y., Del Prete G.Q., Goulder P., Brumme Z.L., et al. Influence of HLA-C expression level on HIV control. Science. 2013;340:87–91. doi: 10.1126/science.1232685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232685</ArticleId><ArticleId IdType="pmc">PMC3784322</ArticleId><ArticleId IdType="pubmed">23559252</ArticleId></ArticleIdList></Reference><Reference><Citation>Viard M., O’hUigin C., Yuki Y., Bashirova A.A., Collins D.R., Urbach J.M., Wolinsky S., Buchbinder S., Kirk G.D., Goedert J.J., et al. Impact of HLA class I functional divergence on HIV control. Science. 2024;383:319–325. doi: 10.1126/science.adk0777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adk0777</ArticleId><ArticleId IdType="pmc">PMC11395297</ArticleId><ArticleId IdType="pubmed">38236978</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilches C., Parham P. KIR: Diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 2002;20:217–251. doi: 10.1146/annurev.immunol.20.092501.134942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.20.092501.134942</ArticleId><ArticleId IdType="pubmed">11861603</ArticleId></ArticleIdList></Reference><Reference><Citation>Caligiuri M.A. Human natural killer cells. Blood. 2008;112:461–469. doi: 10.1182/blood-2007-09-077438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-09-077438</ArticleId><ArticleId IdType="pmc">PMC2481557</ArticleId><ArticleId IdType="pubmed">18650461</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M., Borsellino G., Falco M., Ferrara G.B., Strominger J.L. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc. Natl. Acad. Sci. USA. 1993;90:12000–12004. doi: 10.1073/pnas.90.24.12000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.24.12000</ArticleId><ArticleId IdType="pmc">PMC48113</ArticleId><ArticleId IdType="pubmed">8265660</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturrieta-Zuazo I., Rita C.G., García-Soidán A., de Malet Pintos-Fonseca A., Alonso-Alarcón N., Pariente-Rodríguez R., Tejeda-Velarde A., Serrano-Villar S., Castañer-Alabau J.L., Nieto-Gañán I. Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of COVID-19 Spanish patients. Clin. Immunol. 2020;219:108572. doi: 10.1016/j.clim.2020.108572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108572</ArticleId><ArticleId IdType="pmc">PMC7428760</ArticleId><ArticleId IdType="pubmed">32810602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente L., Martín M.M., Franco A., Barrios Y., Cáceres J.J., Solé-Violán J., Perez A., Ramos-Gómez L., Ojeda N. HLA genetic polymorphisms and prognosis of patients with COVID-19. Med. Intensiv. (Engl. Ed.) 2021;45:96–103. doi: 10.1016/j.medin.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medin.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7474921</ArticleId><ArticleId IdType="pubmed">38620408</ArticleId></ArticleIdList></Reference><Reference><Citation>Correale P., Mutti L., Pentimalli F., Baglio G., Saladino R.E., Sileri P., Giordano A. HLA-B*44 and C*01 prevalence correlates with COVID-19 spreading across Italy. Int. J. Mol. Sci. 2020;21:5205. doi: 10.3390/ijms21155205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21155205</ArticleId><ArticleId IdType="pmc">PMC7432860</ArticleId><ArticleId IdType="pubmed">32717807</ArticleId></ArticleIdList></Reference><Reference><Citation>Littera R., Campagna M., Deidda S., Angioni G., Cipri S., Melis M., Firinu D., Santus S., Lai A., Porcella R., et al. Human leukocyte antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to SARS-CoV-2 infection and severity of the disease course. The Sardinian experience. Front. Immunol. 2020;11:605688. doi: 10.3389/fimmu.2020.605688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.605688</ArticleId><ArticleId IdType="pmc">PMC7746644</ArticleId><ArticleId IdType="pubmed">33343579</ArticleId></ArticleIdList></Reference><Reference><Citation>Vishnubhotla R., Sasikala M., Ketavarapu V., Reddy D.N. High-resolution HLA genotyping identifies alleles associated with severe COVID-19: A preliminary study from India. Immun. Inflamm. Dis. 2021;9:1781–1785. doi: 10.1002/iid3.481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.481</ArticleId><ArticleId IdType="pmc">PMC8426675</ArticleId><ArticleId IdType="pubmed">34289534</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren R.L., Birol I. HLA alleles measured from COVID-19 patient transcriptomes reveal associations with disease prognosis in a New York cohort. PeerJ. 2021;9:e12368. doi: 10.7717/peerj.12368.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.12368</ArticleId><ArticleId IdType="pmc">PMC8522641</ArticleId><ArticleId IdType="pubmed">34722002</ArticleId></ArticleIdList></Reference><Reference><Citation>Snary D., Barnstable C.J., Bodmer W.F., Crumpton M.J. Molecular structure of human histocompatibility antigens: The HLA-C series. Eur. J. Immunol. 1977;7:580–585. doi: 10.1002/eji.1830070816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830070816</ArticleId><ArticleId IdType="pubmed">332508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemmour J., Parham P. Distinctive polymorphism at the HLA-C locus: Implications for the expression of HLA-C. J. Exp. Med. 1992;176:937–950. doi: 10.1084/jem.176.4.937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.176.4.937</ArticleId><ArticleId IdType="pmc">PMC2119399</ArticleId><ArticleId IdType="pubmed">1383381</ArticleId></ArticleIdList></Reference><Reference><Citation>Neefjes J.J., Ploegh H.L. Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: Differential effects of inhibition of glycosylation on class I subunit association. Eur. J. Immunol. 1988;18:801–810. doi: 10.1002/eji.1830180522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830180522</ArticleId><ArticleId IdType="pubmed">2967765</ArticleId></ArticleIdList></Reference><Reference><Citation>McCutcheon J.A., Gumperz J., Smith K.D., Lutz C.T., Parham P. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J. Exp. Med. 1995;181:2085–2095. doi: 10.1084/jem.181.6.2085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.181.6.2085</ArticleId><ArticleId IdType="pmc">PMC2192076</ArticleId><ArticleId IdType="pubmed">7760000</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter G., Heckerman D., Schneidewind A., Fadda L., Kadie C.M., Carlson J.M., Oniangue-Ndza C., Martin M., Li B., Khakoo S.I., et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature. 2011;476:96–100. doi: 10.1038/nature10237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10237</ArticleId><ArticleId IdType="pmc">PMC3194000</ArticleId><ArticleId IdType="pubmed">21814282</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadda L., Körner C., Kumar S., van Teijlingen N.H., Piechocka-Trocha A., Carrington M., Altfeld M. HLA-Cw*0102-restricted HIV-1 p24 epitope variants can modulate the binding of the inhibitory KIR2DL2 receptor and primary NK cell function. PLoS Pathog. 2012;8:e1002805. doi: 10.1371/journal.ppat.1002805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002805</ArticleId><ArticleId IdType="pmc">PMC3395618</ArticleId><ArticleId IdType="pubmed">22807681</ArticleId></ArticleIdList></Reference><Reference><Citation>Hölzemer A., Thobakgale C.F., Jimenez Cruz C.A., Garcia-Beltran W.F., Carlson J.M., van Teijlingen N.H., Mann J.K., Jaggernath M., Kang S.G., Körner C., et al. Selection of an HLA-C*03:04-restricted HIV-1 p24 Gag sequence variant is associated with viral escape from KIR2DL3+ natural killer cells: Data from an observational cohort in South Africa. PLoS Med. 2015;12:e1001900. doi: 10.1371/journal.pmed.1001900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001900</ArticleId><ArticleId IdType="pmc">PMC4648589</ArticleId><ArticleId IdType="pubmed">26575988</ArticleId></ArticleIdList></Reference><Reference><Citation>van Teijlingen N.H., Hölzemer A., Körner C., García-Beltrán W.F., Schafer J.L., Fadda L., Suscovich T.J., Brander C., Carrington M., Evans D.T., et al. Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03:04 and modulate primary natural killer cell function. Aids. 2014;28:1399–1408. doi: 10.1097/QAD.0000000000000284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000000284</ArticleId><ArticleId IdType="pmc">PMC4453925</ArticleId><ArticleId IdType="pubmed">24785948</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Z., Kuroki K., Kuse N., Sun X., Akahoshi T., Qi Y., Chikata T., Naruto T., Koyanagi M., Murakoshi H., et al. HIV-1 control by NK cells via reduced interaction between KIR2DL2 and HLA-C*12:02/C*14:03. Cell Rep. 2016;17:2210–2220. doi: 10.1016/j.celrep.2016.10.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.10.075</ArticleId><ArticleId IdType="pmc">PMC5184766</ArticleId><ArticleId IdType="pubmed">27880898</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler M.C., Nelde A., Weber J.K., Schreitmüller C.M., Martrus G., Huynh T., Bunders M.J., Lunemann S., Stevanovic S., Zhou R., et al. HIV-1 induced changes in HLA-C*03: 04-presented peptide repertoires lead to reduced engagement of inhibitory natural killer cell receptors. Aids. 2020;34:1713–1723. doi: 10.1097/QAD.0000000000002596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000002596</ArticleId><ArticleId IdType="pmc">PMC8635260</ArticleId><ArticleId IdType="pubmed">32501836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunemann S., Martrus G., Hölzemer A., Chapel A., Ziegler M., Körner C., Garcia Beltran W., Carrington M., Wedemeyer H., Altfeld M. Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C*03:04 and modulate NK cell function. J. Hepatol. 2016;65:252–258. doi: 10.1016/j.jhep.2016.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2016.03.016</ArticleId><ArticleId IdType="pmc">PMC4955726</ArticleId><ArticleId IdType="pubmed">27057987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlenstiel G., Martin M.P., Gao X., Carrington M., Rehermann B. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J. Clin. Investig. 2008;118:1017–1026. doi: 10.1172/JCI32400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI32400</ArticleId><ArticleId IdType="pmc">PMC2214845</ArticleId><ArticleId IdType="pubmed">18246204</ArticleId></ArticleIdList></Reference><Reference><Citation>La D., Czarnecki C., El-Gabalawy H., Kumar A., Meyers A.F.A., Bastien N., Simonsen J.N., Plummer F.A., Luo M. Enrichment of variations in KIR3DL1/S1 and KIR2DL2/L3 among H1N1/09 ICU patients: An exploratory study. PLoS ONE. 2011;6:e29200. doi: 10.1371/journal.pone.0029200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029200</ArticleId><ArticleId IdType="pmc">PMC3247251</ArticleId><ArticleId IdType="pubmed">22216211</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M., McWilliam H.E.G., Aktepe T.E., Fritzlar S., Illing P.T., Mifsud N.A., Purcell A.W., Rockman S., Reading P.C., Vivian J.P., et al. Downregulation of MHC class I expression by influenza A and B viruses. Front. Immunol. 2019;10:1158. doi: 10.3389/fimmu.2019.01158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01158</ArticleId><ArticleId IdType="pmc">PMC6548845</ArticleId><ArticleId IdType="pubmed">31191533</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitdemange C., Becquart P., Wauquier N., Béziat V., Debré P., Leroy E.M., Vieillard V. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog. 2011;7:e1002268. doi: 10.1371/journal.ppat.1002268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002268</ArticleId><ArticleId IdType="pmc">PMC3178577</ArticleId><ArticleId IdType="pubmed">21966274</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitdemange C., Wauquier N., Jacquet J.M., Theodorou I., Leroy E., Vieillard V. Association of HLA class-I and inhibitory KIR genotypes in Gabonese patients infected by Chikungunya or Dengue type-2 viruses. PLoS ONE. 2014;9:e108798. doi: 10.1371/journal.pone.0108798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0108798</ArticleId><ArticleId IdType="pmc">PMC4181859</ArticleId><ArticleId IdType="pubmed">25264760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wauquier N., Petitdemange C., Tarantino N., Maucourant C., Coomber M., Lungay V., Bangura J., Debré P., Vieillard V. HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2+ NK cells in Lassa virus infection. EBioMedicine. 2019;40:605–613. doi: 10.1016/j.ebiom.2019.01.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.01.048</ArticleId><ArticleId IdType="pmc">PMC6413685</ArticleId><ArticleId IdType="pubmed">30711514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wauquier N., Padilla C., Becquart P., Leroy E., Vieillard V. Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection. Immunogenetics. 2010;62:767–771. doi: 10.1007/s00251-010-0480-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-010-0480-x</ArticleId><ArticleId IdType="pmc">PMC2978320</ArticleId><ArticleId IdType="pubmed">20878400</ArticleId></ArticleIdList></Reference><Reference><Citation>Wawina-Bokalanga T., Vanmechelen B., Lhermitte V., Martí-Carreras J., Vergote V., Koundouno F.R., Akoi-Boré J., Thom R., Tipton T., Steeds K., et al. Human diversity of killer cell immunoglobulin-like receptors and human leukocyte antigen class I alleles and Ebola virus disease outcomes. Emerg. Infect. Dis. 2021;27:76–84. doi: 10.3201/eid2701.202177.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2701.202177</ArticleId><ArticleId IdType="pmc">PMC7774578</ArticleId><ArticleId IdType="pubmed">33350932</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimini E., Viola D., Cabeza-Cabrerizo M., Romanelli A., Tumino N., Sacchi A., Bordoni V., Casetti R., Turchi F., Martini F., et al. Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Negl. Trop. Dis. 2017;11:e0005645. doi: 10.1371/journal.pntd.0005645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0005645</ArticleId><ArticleId IdType="pmc">PMC5472323</ArticleId><ArticleId IdType="pubmed">28558022</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro de Moura M., Davalos V., Planas-Serra L., Alvarez-Errico D., Arribas C., Ruiz M., Aguilera-Albesa S., Troya J., Valencia-Ramos J., Vélez-Santamaria V., et al. Epigenome-wide association study of COVID-19 severity with respiratory failure. EBioMedicine. 2021;66:103339. doi: 10.1016/j.ebiom.2021.103339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103339</ArticleId><ArticleId IdType="pmc">PMC8047083</ArticleId><ArticleId IdType="pubmed">33867313</ArticleId></ArticleIdList></Reference><Reference><Citation>Littera R., Chessa L., Deidda S., Angioni G., Campagna M., Lai S., Melis M., Cipri S., Firinu D., Santus S., et al. Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection. PLoS ONE. 2021;16:e0255608. doi: 10.1371/journal.pone.0255608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255608</ArticleId><ArticleId IdType="pmc">PMC8341547</ArticleId><ArticleId IdType="pubmed">34352002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S., Shao Z., Ni W., Sun P., Qiao J., Wan H., Huang Y., Liu X., Zhai H., Xiao M., et al. The KIR2DL2/HLA-C1C1 gene pairing is associated with an increased risk of SARS-CoV-2 infection. Front. Immunol. 2022;13:919110. doi: 10.3389/fimmu.2022.919110.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.919110</ArticleId><ArticleId IdType="pmc">PMC9301464</ArticleId><ArticleId IdType="pubmed">35874712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuraba A., Haider H., Sato T. Population difference in allele frequency of HLA-C*05 and its correlation with COVID-19 mortality. Viruses. 2020;12:1333. doi: 10.3390/v12111333.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12111333</ArticleId><ArticleId IdType="pmc">PMC7699862</ArticleId><ArticleId IdType="pubmed">33233780</ArticleId></ArticleIdList></Reference><Reference><Citation>Farias T.D.J., Brugiapaglia S., Croci S., Magistroni P., Curcio C., Zguro K., Fallerini C., Fava F., Pettini F., Kichula K.M., et al. HLA-DPB1*13:01 associates with enhanced, and KIR2DS4*001 with diminished protection from developing severe COVID-19. HLA. 2024;103:e15251. doi: 10.1111/tan.15251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.15251</ArticleId><ArticleId IdType="pmc">PMC10873037</ArticleId><ArticleId IdType="pubmed">37850268</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim M.J.W., Stotz Z., Lu J., Brennan P., Long E.O., Sun P.D. T cells discriminate between groups C1 and C2 HLA-C. Elife. 2022;11:e75670. doi: 10.7554/eLife.75670.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.75670</ArticleId><ArticleId IdType="pmc">PMC9177145</ArticleId><ArticleId IdType="pubmed">35587797</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizar P., Pan D., Kapadia D., Bécares L., Sze S., Taylor H., Amele S., Kibuchi E., Divall P., Gray L.J., et al. Ethnic inequalities in COVID-19 infection, hospitalisation, intensive care admission, and death: A global systematic review and meta-analysis of over 200 million study participants. EClinicalMedicine. 2023;57:101877. doi: 10.1016/j.eclinm.2023.101877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101877</ArticleId><ArticleId IdType="pmc">PMC9986034</ArticleId><ArticleId IdType="pubmed">36969795</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>